metoprolol has been researched along with Neurally Mediated Faint in 27 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metoprolol is a β-adrenergic receptor antagonist that is ineffective in younger patients, but may benefit older (≥40 years) VVS patients." | 6.82 | Rationale for the Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Trial (POST5). ( Benditt, DG; Faris, PD; Krahn, AD; Manns, B; Morillo, CA; Raj, SR; Semeniuk, L; Sheldon, RS, 2016) |
| "Metoprolol is a β-adrenergic receptor antagonist that is ineffective in younger patients, but may benefit older (≥40 years) VVS patients." | 2.82 | Rationale for the Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Trial (POST5). ( Benditt, DG; Faris, PD; Krahn, AD; Manns, B; Morillo, CA; Raj, SR; Semeniuk, L; Sheldon, RS, 2016) |
| "Twenty-eight children and adolescents (8 boys, 20 girls; mean age, 12+/-3 years; age range, 8-17 years) with vasovagal syncope were randomized to receive either metoprolol (metoprolol group; dosage range, 0." | 2.73 | Randomized comparison of metoprolol versus conventional treatment in preventing recurrence of vasovagal syncope in children and adolescents. ( Chen, J; Du, J; Jin, H; Tang, C; Wang, L; Zhang, Q, 2008) |
| "Metoprolol was not effective in preventing vasovagal syncope in the study population." | 2.72 | Prevention of Syncope Trial (POST): a randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope. ( Connolly, S; Fouad-Tarazi, F; Klingenheben, T; Koshman, ML; Krahn, A; Ku, T; Morillo, C; Ritchie, D; Rose, S; Sheldon, R; Talajic, M, 2006) |
| "Few therapies for vasovagal syncope have been proven effective." | 2.71 | Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope; rationale and study design. ( Connolly, S; Rose, S; Sheldon, R, 2003) |
| "Metoprolol was more effective than clonidine in abolishing syncope (19/20 v 1/20, P < 0." | 2.68 | Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine. ( Biffi, M; Boriani, G; Branzi, A; Bronzetti, G; Frabetti, L; Magnani, B; Sabbatani, P; Zannoli, R, 1997) |
| "In the OI spectrum, postural tachycardia syndrome (POTS) accounted for 826 cases (39." | 1.72 | [A 10-year retrospective analysis of spectrums and treatment options of orthostatic intolerance and sitting intolerance in children]. ( Chen, YH; Cui, YX; DU, JB; Jin, HF; Liao, Y; Liu, P; Liu, XQ; Qi, JG; Sun, CF; Sun, Y; Wang, YL; Xu, WR; Yan, H; Zhang, CY; Zhang, QY, 2022) |
| "Metoprolol is an important therapeutic option for children with VVS." | 1.51 | Twenty-four-hour urine NE level as a predictor of the therapeutic response to metoprolol in children with recurrent vasovagal syncope. ( Cai, Z; Kong, Q; Liu, M; Pan, Y; Wang, M; Yang, X; Zhao, C, 2019) |
| "Metoprolol was prescribed to the VVS subjects." | 1.48 | Left Ventricular Ejection Fraction and Fractional Shortening are Useful for the Prediction of the Therapeutic Response to Metoprolol in Children with Vasovagal Syncope. ( Du, J; Jin, H; Li, H; Li, X; Liu, P; Song, J; Tang, C; Wang, Y, 2018) |
| "The diagnosis of vasodepressor syncope was made and anticonvulsant medication was discontinued." | 1.33 | Vasovagal syncope misdiagnosed as epilepsy for 17 years: prime importance of clinical history. ( Garcia, P; Schuger, CD; Smith, BJ; Spanaki, MV, 2006) |
| "As transient loss of consciousness during driving may cause potentially fatal accident, it has to be taken into consideration during decision making for issue of driving licenses to patients with VVS." | 1.31 | Motor vehicle accident with complete loss of consciousness due to vasovagal syncope. ( Lõrincz, I; Szabó, Z; Varga, E; Varga, M; Wórum, F, 2002) |
| " Adverse effects resolved within 1 minute of dose reduction." | 1.31 | Safety and tolerability of an aggressive tilt table test protocol in the evaluation of patients with suspected neurocardiogenic syncope. ( Brodsky, C; Vlay, LC; Vlay, SC, 2000) |
| "Pharmacological therapy of neurocardiogenic syncope is often limited by the relatively low response rate to such treatment." | 1.30 | Prospective evaluation of a two-step therapeutic strategy in neurocardiogenic syncope: midodrine as second line treatment in patients refractory to beta-blockers. ( Credner, S; Hohnloser, SH; Klingenheben, T, 1999) |
| "In 16 patients with neurocardiogenic syncope, changes in endogenous catecholamine concentrations were determined during repeated tilt table testing before and during treatment with metoprolol." | 1.29 | Changes in plasma epinephrine concentration and in heart rate during head-up tilt testing in patients with neurocardiogenic syncope: correlation with successful therapy with beta-receptor antagonists. ( Hohnloser, SH; Kalusche, D; Klingenheben, T; Li, YG; Schöpperl, M, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (29.63) | 18.2507 |
| 2000's | 11 (40.74) | 29.6817 |
| 2010's | 6 (22.22) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, YX | 1 |
| DU, JB | 2 |
| Zhang, QY | 2 |
| Liao, Y | 1 |
| Liu, P | 2 |
| Wang, YL | 2 |
| Qi, JG | 1 |
| Yan, H | 1 |
| Xu, WR | 1 |
| Liu, XQ | 1 |
| Sun, Y | 1 |
| Sun, CF | 1 |
| Zhang, CY | 1 |
| Chen, YH | 1 |
| Jin, HF | 1 |
| Deveau, AP | 1 |
| Sheldon, R | 3 |
| Maxey, C | 2 |
| Ritchie, D | 3 |
| Doucette, S | 1 |
| Parkash, R | 1 |
| Song, J | 1 |
| Li, H | 2 |
| Wang, Y | 1 |
| Li, X | 3 |
| Tang, C | 2 |
| Jin, H | 3 |
| Du, J | 2 |
| Kong, Q | 1 |
| Yang, X | 1 |
| Cai, Z | 1 |
| Pan, Y | 1 |
| Wang, M | 1 |
| Liu, M | 1 |
| Zhao, C | 1 |
| Ng, J | 1 |
| Sheldon, RS | 3 |
| Raj, V | 1 |
| Exner, DV | 1 |
| Raj, SR | 2 |
| Li, Y | 1 |
| Faris, PD | 1 |
| Semeniuk, L | 1 |
| Manns, B | 1 |
| Krahn, AD | 2 |
| Morillo, CA | 2 |
| Benditt, DG | 1 |
| Klingenheben, T | 4 |
| Sheldon, A | 1 |
| Rose, MS | 1 |
| Varga, E | 1 |
| Wórum, F | 1 |
| Szabó, Z | 1 |
| Varga, M | 1 |
| Lõrincz, I | 1 |
| Rose, S | 2 |
| Connolly, S | 2 |
| Alegria, JR | 1 |
| Gersh, BJ | 1 |
| Scott, CG | 1 |
| Hodge, DO | 1 |
| Hammill, SC | 1 |
| Shen, WK | 1 |
| Mizumaki, K | 1 |
| Fujiki, A | 1 |
| Sakabe, M | 1 |
| Nishida, K | 1 |
| Sugao, M | 1 |
| Tsuneda, T | 1 |
| Nagasawa, H | 1 |
| Inoue, H | 1 |
| Krahn, A | 1 |
| Morillo, C | 1 |
| Talajic, M | 1 |
| Ku, T | 1 |
| Fouad-Tarazi, F | 1 |
| Koshman, ML | 1 |
| Spanaki, MV | 1 |
| Garcia, P | 1 |
| Schuger, CD | 1 |
| Smith, BJ | 1 |
| Zhen, JL | 1 |
| Li, WZ | 1 |
| Zhang, Q | 1 |
| Wang, L | 1 |
| Chen, J | 1 |
| Kalusche, D | 1 |
| Li, YG | 1 |
| Schöpperl, M | 1 |
| Hohnloser, SH | 2 |
| Natale, A | 1 |
| Newby, KH | 1 |
| Dhala, A | 1 |
| Akhtar, M | 1 |
| Sra, J | 1 |
| Biffi, M | 1 |
| Boriani, G | 1 |
| Sabbatani, P | 1 |
| Bronzetti, G | 1 |
| Frabetti, L | 1 |
| Zannoli, R | 1 |
| Branzi, A | 1 |
| Magnani, B | 1 |
| Pentousis, D | 1 |
| Cooper, JP | 1 |
| Cobbe, SM | 1 |
| Deal, BJ | 1 |
| Strieper, M | 1 |
| Scagliotti, D | 1 |
| Hulse, E | 1 |
| Auld, D | 1 |
| Campbell, R | 1 |
| Strasburger, JF | 1 |
| Benson, DW | 1 |
| Smith, W | 1 |
| Credner, S | 1 |
| Cohen, TJ | 1 |
| Cayenne, S | 1 |
| Black, M | 1 |
| Doolittle, S | 1 |
| Ibrahim, B | 1 |
| Quan, W | 1 |
| Vlay, SC | 1 |
| Brodsky, C | 1 |
| Vlay, LC | 1 |
| Nakagawa, M | 1 |
| Takahashi, N | 1 |
| Yufu, K | 1 |
| Fujino, T | 1 |
| Ooie, T | 1 |
| Yonemochi, H | 1 |
| Nobe, S | 1 |
| Hara, M | 1 |
| Saikawa, T | 1 |
| Ito, M | 1 |
| Ventura, R | 1 |
| Maas, R | 1 |
| Zeidler, D | 1 |
| Schoder, V | 1 |
| Nienaber, CA | 1 |
| Schuchert, A | 1 |
| Meinertz, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects[NCT02123056] | Phase 4 | 52 participants (Actual) | Interventional | 2014-10-31 | Active, not recruiting | ||
| CardioneuROablation for Reflex Syncope: Effects on autonoMic cArdiac Regulation and Efficacy Assessment - the Roman Syncope Study.[NCT03903744] | 48 participants (Actual) | Interventional | 2018-11-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 trials available for metoprolol and Neurally Mediated Faint
| Article | Year |
|---|---|
Sex Differences in Vasovagal Syncope: A Post Hoc Analysis of the Prevention of Syncope Trials (POST) I and II.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Canada; Electrocardiography; Fem | 2020 |
Quality of life improves in vasovagal syncope patients after clinical trial enrollment regardless of fainting in follow-up.
Topics: Adult; Cost of Illness; Female; Fludrocortisone; Follow-Up Studies; Humans; Male; Metoprolol; Patien | 2019 |
Rationale for the Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Trial (POST5).
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Aging; Dose-Response Relationship, D | 2016 |
Age-dependent effect of β-blockers in preventing vasovagal syncope.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Double-Blind Method; Female; Humans; Male; Metoprol | 2012 |
Prevention of Syncope Trial (POST): a randomized clinical trial of beta blockers in the prevention of vasovagal syncope; rationale and study design.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Humans; Metoprolol; Middle Aged; Prospective Studies; Qual | 2003 |
Prevention of Syncope Trial (POST): a randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Double-Blind Method; Female; Humans; Incidence; Mal | 2006 |
[Hemodynamic changes during head-up tilt test and predictive value thereof in predicting the efficacy of metoprolol therapy in children with vasovagal syncope].
Topics: Adolescent; Adrenergic beta-Antagonists; Blood Pressure; Child; Female; Heart Rate; Humans; Male; Me | 2007 |
Randomized comparison of metoprolol versus conventional treatment in preventing recurrence of vasovagal syncope in children and adolescents.
Topics: Adolescent; Child; Female; Humans; Male; Metoprolol; Secondary Prevention; Syncope, Vasovagal | 2008 |
Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine.
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Clonidine; Cross-Over Stu | 1997 |
A randomized and controlled pilot trial of beta-blockers for the treatment of recurrent syncope in patients with a positive or negative response to head-up tilt test.
Topics: Adrenergic beta-Antagonists; Adult; Disease-Free Survival; Female; Humans; Male; Metoprolol; Middle | 2002 |
17 other studies available for metoprolol and Neurally Mediated Faint
| Article | Year |
|---|---|
[A 10-year retrospective analysis of spectrums and treatment options of orthostatic intolerance and sitting intolerance in children].
Topics: Child; Electrolytes; Female; Humans; Male; Metoprolol; Midodrine; Orthostatic Intolerance; Postural | 2022 |
Left Ventricular Ejection Fraction and Fractional Shortening are Useful for the Prediction of the Therapeutic Response to Metoprolol in Children with Vasovagal Syncope.
Topics: Adolescent; Adrenergic beta-Antagonists; Case-Control Studies; Child; Echocardiography, Doppler, Col | 2018 |
Twenty-four-hour urine NE level as a predictor of the therapeutic response to metoprolol in children with recurrent vasovagal syncope.
Topics: Adolescent; Blood Pressure; Case-Control Studies; Child; Female; Humans; Male; Metoprolol; Norepinep | 2019 |
Prognostic analysis of orthostatic intolerance using survival model in children.
Topics: Adolescent; Child; Female; Humans; Male; Metoprolol; Midodrine; Orthostatic Intolerance; Prognosis; | 2014 |
Motor vehicle accident with complete loss of consciousness due to vasovagal syncope.
Topics: Accidents, Traffic; Adrenergic beta-Antagonists; Humans; Male; Metoprolol; Middle Aged; Secondary Pr | 2002 |
Comparison of frequency of recurrent syncope after beta-blocker therapy versus conservative management for patients with vasovagal syncope.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Comorbidity; Female; Humans; Male; Metoprolol; M | 2003 |
Dynamic changes in the QT-R-R relationship during head-up tilt test in patients with vasovagal syncope.
Topics: Adrenergic beta-Antagonists; Adult; Autonomic Nervous System; Case-Control Studies; Chi-Square Distr | 2005 |
Vasovagal syncope misdiagnosed as epilepsy for 17 years: prime importance of clinical history.
Topics: Adrenergic beta-Antagonists; Adult; Diagnosis, Differential; Diagnostic Errors; Epilepsy; Humans; Ma | 2006 |
Changes in plasma epinephrine concentration and in heart rate during head-up tilt testing in patients with neurocardiogenic syncope: correlation with successful therapy with beta-receptor antagonists.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Electrocardiography, Ambulatory; Epinephrine; Female; Hear | 1996 |
Response to beta blockers in patients with neurocardiogenic syncope: how to predict beneficial effects.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Electrocardiography; Female; Follow-Up | 1996 |
Prolonged asystole induced by head up tilt test. Report of four cases and brief review of the prognostic significance and medical management.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Disopyramide; Female; Heart | 1997 |
The medical therapy of cardioinhibitory syncope in pediatric patients.
Topics: Adrenergic Agonists; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Child; Cohort Studies; Disopy | 1997 |
Malignant vasovagal syncope: a randomised trial of metoprolol and clonidine.
Topics: Adrenergic beta-Agonists; Antihypertensive Agents; Clonidine; Humans; Isoproterenol; Metoprolol; Syn | 1998 |
Prospective evaluation of a two-step therapeutic strategy in neurocardiogenic syncope: midodrine as second line treatment in patients refractory to beta-blockers.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Clinical Protocols; Female; Follow-Up Studie | 1999 |
The effects of intrinsic sympathomimetic activity on beta-blocker efficacy for treatment of neurocardiogenic syncope.
Topics: Acebutolol; Adrenergic beta-Antagonists; Adult; Aged; Atenolol; Female; Humans; Male; Metoprolol; Mi | 1999 |
Safety and tolerability of an aggressive tilt table test protocol in the evaluation of patients with suspected neurocardiogenic syncope.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Dose-Response Relationship, Dru | 2000 |
Malignant neurocardiogenic vasovagal syncope associated with chronic exaggerated vagal tone.
Topics: Adult; Arrhythmia, Sinus; Electrocardiography; Female; Heart Rate; Humans; Metoprolol; Posture; Refe | 2000 |